#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	16200	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2528	790.1	0	.	n	.	0	A69G	SNP	69	69	A	557	557	G	1022	G,T	1021,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	16200	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2528	790.1	0	.	n	.	0	C1450T	SNP	1450	1450	C	1938	1938	T	1111	T,G,C	1108,2,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	16200	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2528	790.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1672	1672	C	1027	C,T	1026,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28050	23S	2890	2890	99.93	23S.l6.c30.ctg.1	4195	834.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	1941	1941	A	1119	A,T	1118,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28050	23S	2890	2890	99.93	23S.l6.c30.ctg.1	4195	834.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2575	2575	C	893	C,A	891,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28050	23S	2890	2890	99.93	23S.l6.c30.ctg.1	4195	834.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2649	2649	A	831	A,C	830,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28050	23S	2890	2890	99.93	23S.l6.c30.ctg.1	4195	834.2	1	SNP	n	C2597T	0	.	.	2597	2597	C	3201	3201	C	1003	C,T,A	995,4,3	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_X_01360c	folP.WHO_X_01360c	1	1	539	2334	folP	852	852	99.88	folP.l6.c30.ctg.1	1962	148.1	0	.	p	.	0	E151K	NONSYN	451	453	GAA	1024	1026	AAA	239;239;240	A;A,C;A	239;237,2;240	.	.
folP.WHO_X_01360c	folP.WHO_X_01360c	1	1	539	2334	folP	852	852	99.88	folP.l6.c30.ctg.1	1962	148.1	1	SNP	p	R228S	1	.	.	682	684	AGC	1255	1257	AGC	231;231;232	A;G;C	231;231;232	folP.WHO_X_01360c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5832	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3933	184.9	1	SNP	p	S91F	0	.	.	271	273	TCC	838	840	TCC	188;188;188	T;C;C,T	188;188;187,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5832	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3933	184.9	1	SNP	p	D95N	0	.	.	283	285	GAC	850	852	GAC	194;195;194	G;A;C	194;195;194	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5832	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3933	184.9	1	SNP	p	D95G	0	.	.	283	285	GAC	850	852	GAC	194;195;194	G;A;C	194;195;194	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	27	2094	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1830	142.3	1	SNP	p	G45D	0	.	.	133	135	GGC	732	734	GGC	243;247;249	G;G;C	243;247;249	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1218	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1312	115.6	0	.	n	.	0	A197.	DEL	197	197	A	755	755	A	234	A	234	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5728	parC	2304	2304	99.91	parC.l6.c17.ctg.1	3446	207.4	1	SNP	p	D86N	0	.	.	256	258	GAC	867	869	GAC	264;265;266	G;A,C;C	264;263,2;266	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5728	parC	2304	2304	99.91	parC.l6.c17.ctg.1	3446	207.4	1	SNP	p	S87I	0	.	.	259	261	AGT	870	872	AGT	270;268;269	A;G,T;T,A	270;267,1;268,1	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5728	parC	2304	2304	99.91	parC.l6.c17.ctg.1	3446	207.4	1	SNP	p	S87W	0	.	.	259	261	AGT	870	872	AGT	270;268;269	A;G,T;T,A	270;267,1;268,1	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5728	parC	2304	2304	99.91	parC.l6.c17.ctg.1	3446	207.4	1	SNP	p	S87R	0	.	.	259	261	AGT	870	872	AGT	270;268;269	A;G,T;T,A	270;267,1;268,1	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5728	parC	2304	2304	99.91	parC.l6.c17.ctg.1	3446	207.4	1	SNP	p	S88P	0	.	.	262	264	TCC	873	875	TCC	269;269;269	T;C;C	269;269;269	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4618	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3184	180.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1852	1854	GGC	238;237;235	G,T;G,C;C	236,2;236,1;235	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	539	4246	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2746	192.8	0	.	p	.	0	K8E	NONSYN	22	24	AAG	474	476	GAG	187;184;185	G,T;A,G;G,C	186,1;183,1;184,1	.	.
penA.9.001	penA.9.001	1	1	539	4246	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2746	192.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1383	1385	GCA	246;245;244	G;C;A	246;245;244	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	4246	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2746	192.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1386	1388	ATC	244;244;244	A;T,G;C	243;240,3;243	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	4246	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2746	192.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1398	1400	GTG	240;240;243	G;T,G;G,A	239;238,1;241,1	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	4246	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2746	192.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1398	1400	GTG	240;240;243	G;T,G;G,A	239;238,1;241,1	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	4246	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2746	192.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1902	1904	ACC	245;246;246	A,T,G,C;C,A;C	242,1,1,1;245,1;246	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	4246	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2746	192.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1956	1958	GCG	241;240;240	G,A;C,G;G	240,1;239,1;240	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	4246	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2746	192.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1956	1958	GCG	241;240;240	G,A;C,G;G	240,1;239,1;240	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	4246	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2746	192.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2079	2081	GGC	272;269;269	G;G,T;C	272;268,1;269	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	4246	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2746	192.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2088	2090	GGC	265;264;265	G;G,T;C,A	265;263,1;264,1	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	539	4246	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2746	192.8	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2106	2108	CTG	269;270;270	C;T,G;G	269;269,1;270	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6054	ponA	2397	2397	100.0	ponA.l15.c17.ctg.1	3551	212.6	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1826	1828	CCG	218;219;221	C;C,T;G,A	218;218,1;220,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2526	porA	1146	1146	99.65	porA.l6.c17.ctg.1	2189	143.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	722	722	C	201	C,G,A	199,1,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	352	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	375	29.0	0	.	p	.	0	V258L	NONSYN	772	774	GTA	14	16	TTA	24;24;27	T;T;A	24;24;27	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	352	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	375	29.0	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	59	61	CAT	59;59;59	C;A;T	59;59;59	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	352	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	375	29.0	0	.	p	.	0	D274S	NONSYN	820	822	GAT	62	64	AGT	59;59;59	A;G;T	59;58;59	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	352	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	375	29.0	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	71	73	TAC	59;59;59	T;A;C	59;59;59	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	352	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	375	29.0	0	.	p	.	0	R307A	NONSYN	919	921	AGA	161	163	GCA	2;2;2	G;C;A	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	352	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	375	29.0	0	.	p	.	0	T311A	NONSYN	931	933	ACA	173	175	GCA	3;3;3	G;C;A	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	352	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	375	29.0	0	.	p	.	0	E312D	NONSYN	934	936	GAA	176	178	GAC	3;3;3	G;A;C	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	352	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	375	29.0	0	.	p	.	0	F314I	NONSYN	940	942	TTC	182	184	ATC	3;3;3	A;T;C	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	352	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	375	29.0	0	.	p	.	0	A316S	NONSYN	946	948	GCG	188	190	TCG	3;3;3	T;C;G	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	352	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	375	29.0	0	.	p	.	0	V318A	NONSYN	952	954	GTC	194	196	GCC	3;3;3	G;C;C	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	352	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	375	29.0	0	.	p	.	0	G319S	NONSYN	955	957	GGC	197	199	AGC	3;3;3	A;G;C	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	352	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	375	29.0	0	.	p	.	0	G320A	NONSYN	958	960	GGT	200	202	GCC	3;3;3	G;C;C	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	352	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	375	29.0	0	.	p	.	0	G322V	NONSYN	964	966	GGT	206	208	GTT	3;3;3	G,T;T;T	2,1;3;3	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3328	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	2012	205.7	0	.	p	.	0	N38E	NONSYN	112	114	AAT	720	722	GAA	296;298;301	G;A;A	296;298;301	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3328	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	2012	205.7	0	.	p	.	0	N134D	NONSYN	400	402	AAT	1008	1010	GAT	278;274;278	G,T;A,C,G;T	277,1;271,2,1;278	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3328	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	2012	205.7	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1131	1133	TCA	286;285;284	T,C;C;A	285,1;285;284	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3328	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	2012	205.7	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1260	1262	GTC	279;278;273	G,T;T;C	278,1;278;273	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3328	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	2012	205.7	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1272	1274	TCT	264;266;266	T,G;C;T	263,1;266;266	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3328	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	2012	205.7	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1590	1592	GCA	256;255;257	G;C;A,C	256;255;256,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3328	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	2012	205.7	1	SNP	p	G120K	1	.	.	358	360	AAG	966	968	AAG	275;275;276	A,C;A;G,T,C	274,1;275;274,1,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3328	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	2012	205.7	1	SNP	p	D121N	0	.	.	361	363	GAC	969	971	GAC	277;282;281	G;A;C,A	277;282;278,3	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3328	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	2012	205.7	1	SNP	p	A121D	1	.	.	361	363	GAC	969	971	GAC	277;282;281	G;A;C,A	277;282;278,3	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	11304	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5226	269.5	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2169	2171	AAT	279;275;272	A;A;T,G,A	279;275;270,1,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1638	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1429	142.9	1	SNP	p	V57M	1	.	.	169	171	ATG	737	739	ATG	296;296;294	A;T;G	296;296;294	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
